Research peptide · Vasoactive intestinal peptide
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
| Name | VIP (vasoactive intestinal peptide) |
| Sequence | Natural 28-amino-acid peptide |
| Molecular weight | ≈3.33 kDa |
| Form | Lyophilized powder |
| Strength per vial | 10 mg |
| Box contents | 10 vials of identical strength |
| Purity | ≥99 % (HPLC) |
VIP is an endogenous neuropeptide of 28 amino acids, characterized in research through the receptors VPAC1 and VPAC2. Both subtypes belong to the secretin family of G protein-coupled receptors and couple through Gs. Agonist binding raises cytoplasmic cAMP and activates protein kinase A. VIP and PACAP share part of this receptor profile, so binding and functional assays often run both ligands in parallel. In intestinal, neural, and immune cell models, lines express VIP receptors at different densities. The synthetic peptide mirrors those cascades in controlled in vitro systems and serves as a reference agonist for adenylate cyclase activity and downstream gene expression. Teams that buy VIP take the vasoactive intestinal peptide at 10 mg per vial.
Lyophilized VIP powder is reconstituted in the laboratory with a suitable sterile solvent. The solvent is added slowly along the vessel wall, then the preparation is mixed gently until the peptide has dissolved fully. Once in solution, VIP is more sensitive to ambient conditions, so further work proceeds promptly. Until use, the reagent is kept away from direct light. Concentration and volume are set by the laboratory in its own protocol. This description does not fix dilution volumes.
In vitro research uses VIP as the reference ligand in competitive binding assays at VPAC1 and VPAC2 and in cAMP accumulation assays that quantify agonist potency against other secretin-family ligands. Neuronal and glial cultures use VIP to follow synchronized cell responses, neuroprotection signals, and the release of inflammatory mediators after peptide stimulation. Immune and epithelial cell models use VIP to track MAPK and cAMP-dependent readouts. Ready solubility after reconstitution supports defined dilution series for concentration-response curves in second-messenger and reporter-gene assays.
Each batch is tested by HPLC for peptide content and purity, and purity stands at ≥99 %. An identity check confirms the 28-amino-acid backbone of the molecule. Results are recorded per batch and apply to the 10 mg strength supplied. This analytical profile supports reproducible binding data and parallel cAMP measurement series in the laboratory.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Ten vials with identical contents. 10 mg per vial → 100 mg per box.
No. All ten vials are unlabelled. Product identification appears exclusively on the outer kit packaging.
The labelled single vial in the product image is illustrative. The same image is used for all strengths of this product; your selected variant determines the contents.
For research use only. Not for human or animal use, diagnosis, therapy or consumption.
5-Amino-1MQ
AHK-Cu
AOD-9604
B12
BAC Water 10 ml
BPC-157
Cagrilintide 5 mg
CJC-1295 (Mod GRF 1-29)
